Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Current Assets (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Current Assets for 13 consecutive years, with $96.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 51.02% to $96.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $96.8 million, a 51.02% increase, with the full-year FY2025 number at $96.8 million, up 51.02% from a year prior.
  • Current Assets was $96.8 million for Q4 2025 at Niagen Bioscience, up from $93.6 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $96.8 million in Q4 2025 to a low of $37.9 million in Q3 2022.
  • A 5-year average of $57.1 million and a median of $49.3 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 33.53% in 2022, then surged 79.57% in 2025.
  • Niagen Bioscience's Current Assets stood at $48.9 million in 2021, then fell by 4.78% to $46.6 million in 2022, then increased by 6.37% to $49.5 million in 2023, then grew by 29.41% to $64.1 million in 2024, then skyrocketed by 51.02% to $96.8 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Current Assets are $96.8 million (Q4 2025), $93.6 million (Q3 2025), and $86.7 million (Q2 2025).